Becton Dickinson and Co (NYSE:BDX) announced a quarterly dividend on Monday, November 25th, RTT News reports. Shareholders of record on Tuesday, December 10th will be paid a dividend of 0.79 per share by the medical instruments supplier on Tuesday, December 31st. This represents a $3.16 annualized dividend and a yield of 1.24%. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77.
Shares of NYSE BDX opened at $255.22 on Wednesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.73 and a current ratio of 1.19. The company has a market cap of $67.46 billion, a PE ratio of 21.85, a P/E/G ratio of 1.76 and a beta of 1.09. The business has a 50-day simple moving average of $250.77 and a two-hundred day simple moving average of $248.02. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $264.74.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping the consensus estimate of $3.30 by $0.01. The business had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company earned $2.93 earnings per share. On average, sell-side analysts predict that Becton Dickinson and will post 12.57 earnings per share for the current fiscal year.
In other news, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the transaction, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Alexandre Conroy sold 9,829 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $255.06, for a total value of $2,506,984.74. Following the completion of the transaction, the executive vice president now owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,174 shares of company stock valued at $8,354,013. Company insiders own 0.12% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.